Allianz’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Allianz’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-850	Closed	-$58.2K	–	481
2024 Q2	$58.2K	Hold	850	–	–	﹤0.01%	389
2024 Q1	$58.8K	Buy	+850	New	+$58.4K	﹤0.01%	396

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz's ITCI Position: Q3 2024 in Review

Allianz sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 850 shares — an estimated $58.2K sold.

Allianz first reported a position in ITCI in Q1 2024 and held it in 2 quarters. The position peaked at $58.8K in Q1 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Allianz reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Allianz sold 850 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $58.2K.
Allianz first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 2 quarters.
Allianz's Intra-Cellular Therapies Inc. position peaked at $58.8K in Q1 2024.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Allianz's 13F filing for Q3 2024, filed 12 May 2025.